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OBJECTIVES: To evaluate the cost effectiveness of
capecitabine + docetaxel combination versus docetaxel
alone in the treatment of advanced and/or metastatic
breast cancer in France. METHODS: This analysis was
based on primary data from an open-label, randomized,
multi-centre phase III clinical trial (SO14999). Unit costs
reﬂecting the French economic context was attached to
patients’ use of resource, i.e. reference tariffs for consul-
tations, daily treatment costs for drugs and mean cost per
DRG for hospitalizations. Direct medical costs were ana-
lyzed from a “payer” perspective, including payments
from the public health insurance, private supplementary
health insurers, and patients’ co-payment. Signiﬁcant dif-
ferences in costs were identiﬁed with a Student’s t-test for
the means. To calculate incremental cost-effectiveness, the
additional cost in the capecitabine arm was divided by
the additional years of life saved. The time horizon of the
clinical trial was 15 months and cost and health effects
were not discounted. RESULTS: Survival was longer in
the combination arm (mean 442 days versus 352 days).
The cost of capecitabine amounted to €1786, while the
cost of docetaxel was signiﬁcantly reduced in the combi-
nation group (€6089 versus €7856; p < 0.0001). None of
the other cost components differed between treatment
groups, and the overall direct medical cost was compa-
rable in the combination group (€9888 ± 343) and in the
monotherapy group (€9852 ± 378; p = 0.9436). The addi-
tional cost in the combination arm was €36 and the clin-
ical beneﬁt was 0.23 life-year saved. Thus, the cost per
life-year saved ratio was estimated to €157. CONCLU-
SIONS: Capecitabine/docetaxel combination appears as a
highly cost-effective strategy in comparison to docetaxel
monotherapy in the treatment of advanced or metastatic
breast cancer in France, while these results derived from
a randomized clinical trial need to be conﬁrmed in current
practice.
SESSION IV
QUALITY OF LIFE OUTCOMES II
QL5
RESPONSIVENESS TO CHANGE OF THE SHORT
FORM (SF)-12 HEALTH STATUS INSTRUMENT IN
PATIENTS WITH CEREBROVASCULAR DISEASE
Müller-Nordhorn J1, Nolte CH2, Rossnagel K1,
Jungehülsing GJ2, Reich A1, Roll S1,Villringer A2,Willich SN1
1Institute of Social Medicine, Epidemiology, and Health
Economics, Berlin, Germany; 2Department of Neurology,
Berlin, Germany
OBJECTIVES: The generic Short Form (SF)-36 is one of
the most commonly used health status instruments in
patients with cerebrovascular disease. However, a respon-
siveness to change—a pre-requisite for evaluative pur-
poses—has not yet been assessed for neither the SF-36 
nor its shortened version, the SF-12. Responsiveness to
change describes the ability of health status instruments
to detect clinically meaningful changes in HRQoL
(health-related quality of life) over time. The main objec-
tive of the present study was, therefore, to determine
responsiveness to change of the SF-12 questionnaire in
patients with stroke and TIA. METHODS: Patients with
stroke/TIA were included at admission to one of the four
participating hospitals. HRQoL was assessed with the
Physical (PCS-12) and Mental (MCS-12) Component
Summary scales at baseline and after 12 months. Respon-
siveness to change was determined with the standardized
response mean (SRM) and classiﬁed as small (SRM
0.20–0.49), moderate (0.50–0.79) or large (≥0.80). SRMs
were calculated separately for patients after stroke and
TIA, and according to stroke severity as measured with
the NIH (National Institutes of Health) stroke scale.
RESULTS: A total of 558 patients was included (55%
men, mean (standard deviation) age 65 (13) years; 45%
women, 69 (14) years). Indications for admission were
stroke (74%) and TIA (26%). In patients with stroke,
SRMs were moderate for both the PCS-12 (SRM 0.5;
absolute change -5.9 (12)) and the MCS-12 (SRM 0.5; 
-6.6 (13)). In patients with TIA, SRMs were below 0.2
for the PCS-12 (absolute change -0.7 (11)) and 0.3 for
the MCS-12 (-3.7 (11)). SRMs increased with stroke
severity as indicated by the NIH stroke scale score. CON-
CLUSIONS: The SF-12 summary scales show a moder-
ate responsiveness to change in patients after stroke.
Responsiveness to change was higher in patients with
increased stroke severity.
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OBJECTIVE: The EQ-5D is a standardized, non-
disease-speciﬁc instrument for describing and valuing
patients’ health-related quality of life. The purpose of this
study is to evaluate psychometric properties of the EQ-
5D in patients with irritable bowel syndrome (IBS).
METHODS: Data from 4 European studies was assessed:
2 studies from the UK (n = 161 and 305 IBS patients), 
1 from Spain (n = 517), and 1 from Germany (n = 100).
Measures used to examine the EQ-5D included the SF-
36, the Irritable Bowel Syndrome—Quality of Life (IBS-
QOL) scale, and both subjective and clinical global
assessments of IBS. Convergent validity was assessed
using SF-36 and IBS-QOL data, discriminate validity
using global ratings of severity, and responsiveness by
subjective and physician assessment of condition. All sub-
